STAAR Surgical Company (STAA)AQR Arbitrage LLC added to its stake +284K shares

915K

Shares reported · +284K vs prior quarter

0.56%

Disclosed portfolio weight

$21.1M

Reported value

Holdings as of

Dec 31, 2025

Filed

Feb 17, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jan 6, 2026Company filing · Form 8-K · Agreement ended, Shareholder voteEnded an important agreement, and held a shareholder vote
2. Jan 14, 2026Company filing · Form 8-K · Material agreement, Listing noticeReceived a notice from its stock exchange, and changed a top executive or board member (and 2 more items)“On January 15, 2026, the Company announced that Stephen C. Farrell, the Company’s Chief Executive Officer and a member of the Board has agreed, at the Board’s request, to step down as a member of the Board, effective January 14, 2026, and that his service as Chief Executive Officer will terminate on January 31, 2026 or such earlier date as is determined by the Board.”
3. Jan 15, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On January 15, 2026, the Board of Directors (the “Board”) of STAAR Surgical Company (the “Company”) elected a new Board Chair, approved changes to the composition and leadership of the Board’s three standing committees, and established two new Board committees.”
4. Feb 1, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On February 1, 2026, the Board of Directors (the “Board”) of STAAR Surgical Company (the “Company”) appointed Warren Foust and Deborah Andrews as Interim Co-Chief Executive Officers, effective February 1, 2026 (the “Effective Date”).”
5. Feb 5, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On February 4, 2026, STAAR Surgical Company (the “Company”) entered into a letter agreement with Nathaniel Sisitsky, the Company’s Chief Legal Officer and Corporate Secretary (the “Letter Agreement”), that provides for Mr. Sisitsky’s termination of employment, effective as of February 4, 2026 (the “Separation Date”).”

What came next

1. Mar 3, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
2. May 12, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
3. Jun 9, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On June 8, 2026, the Compensation Committee (the “Committee”) of the Board of Directors of STAAR Surgical Company (the “Company”) approved an increase to the annual base salary of Deborah Andrews, the Company's Interim Co-Chief Executive Officer and Chief Financial Officer from $512,000 to $575,000.”

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for STAAR Surgical Company

OQRO holds no insider, Congress, fund or contract record for STAAR Surgical Company dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its STAA page.

How this filing works

• SEC Form 13F

Other disclosures at STAAR Surgical Company

• SEC Form 13F-HRMay 15, 2026
• SEC Form 13F-HRNov 14, 2025
• SEC Form 4Apr 10, 2025
• SEC Form 4Apr 10, 2025
• SEC Form 4Apr 10, 2025
• SEC Form 4Apr 10, 2025

Everything OQRO holds on this company is on its STAA page.